首页> 外文期刊>Pediatric clinics of North America >Recent advances in the treatment of bronchiolitis and laryngitis.
【24h】

Recent advances in the treatment of bronchiolitis and laryngitis.

机译:毛细支气管炎和喉炎的治疗新进展。

获取原文
获取原文并翻译 | 示例
       

摘要

Progress has been made in the treatment for patients with croup and bronchiolitis in the past decade. By intervening with pharmacologic agents, a better outcome has been documented in children with these diseases. A lower probability of hospital admission means that fewer health care dollars need to be expended in this area. The present state of evidence substantiates the following. Bronchiolitis . Nebulized albuterol causes significant short-term improvement in clinical scores in bronchiolitic children, but there is no evidence that it reduces admission rates or decreases length of hospitalization. . Nebulized epinephrine results in significant improvement in clinical scores and airway resistance in children hospitalized with bronchiolitis and in the emergency department causes acute improvement in oxygenation, decreases length of time in the emergency department and admission rate to hospital. . There is no evidence to support the use of dexamethasone or other glucocorticosteroids for infants hospitalized with bronchiolitis. Croup . Nebulized budesonide or oral dexamethasone results in acute clinical improvement in outpatients with mild to moderate croup, reducing the need for hospitalization. . A combination of nebulized budesonide and oral dexamethasone may provide the best clinical outcome, although further evidence is needed to substantiate this . The required dose of oral dexamethasone may range from 0.15 mg/kg to 0.6 mg/kg for best clinical outcome. . Use of racemic epinephrine or L-epinephrine in the emergency department, especially when used concomitantly with glucocorticoids, does not require automatic hospital admission; a 3-hour observation period in the emergency department may suffice. . Use of intramuscular dexamethasone is difficult to justify in patients with croup who are able to ingest oral medications. Future studies need to examine dosing of glucocorticoids for inpatients with croup. In addition, an important question remains as to whether very mild croup patients (those with no evidence of respiratory distress) might benefit from glucocorticoids administered in the physician's office or the emergency department.
机译:在过去的十年中,在流行性腮腺炎和细支气管炎患者的治疗方面取得了进展。通过干预药物治疗,已证明患有这些疾病的儿童有较好的预后。较低的住院率意味着在该领域需要花费更少的医疗保健费用。目前的证据证实了以下事实。细支气管炎 。雾化的沙丁胺醇可导致支气管滑脱儿童的临床评分短期显着改善,但没有证据表明其降低入院率或缩短住院时间。 。雾化的肾上腺素可显着改善住院的细支气管炎患儿的临床评分和气道阻力,而急诊科则可显着改善氧合作用,缩短急诊科的时间长度和住院率。 。没有证据支持在患有毛细支气管炎住院的婴儿中使用地塞米松或其他糖皮质激素。副总裁。雾化的布地奈德或口服地塞米松可使轻度至中度臀部病的门诊患者获得急性临床改善,从而减少了住院需求。 。雾化的布地奈德和口服地塞米松的组合可能提供最佳的临床效果,尽管需要进一步的证据来证实这一点。口服地塞米松的所需剂量范围为0.15 mg / kg至0.6 mg / kg,以获得最佳临床效果。 。在急诊室使用消旋肾上腺素或L-肾上腺素,尤其是与糖皮质激素同时使用时,不需要自动入院;在急诊室进行三个小时的观察就足够了。 。对于能够摄取口服药物的croup患者,难以证明使用肌内地塞米松是合理的。未来的研究需要检查糖耐量异常患者的糖皮质激素剂量。此外,一个非常重要的问题仍然是,对于非常轻微的臀部病患者(没有呼吸窘迫迹象的患者)是否可以从医师办公室或急诊室使用的糖皮质激素中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号